Results 111 to 120 of about 12,266 (204)

PDE5 inhibitors protect against post-infarction heart failure

Frontiers in Bioscience, 2016
Heart failure (HF) is one of the main causes for cardiovascular morbidity and mortality. This study was designed to examine the effect of PDE-5 inhibition on cardiac geometry, function and apoptosis in post-infarct HF. Our data revealed that treatment of the PDE-5 inhibitor sildenafil, beginning 3 days after left anterior descending coronary artery ...
Na, Li, Yuan, Yuan, Shuang, Li, Cao, Zeng, Wenjun, Yu, Mingzhi, Shen, Rongqing, Zhang, Congye, Li, Yingmei, Zhang, Haichang, Wang   +9 more
openaire   +2 more sources

Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment. [PDF]

, 2020
Altered metabolism in pulmonary artery smooth muscle cells (PASMCs) and endothelial cells (PAECs) contributes to the pathology of pulmonary hypertension (PH), but changes in substrate uptake and how substrates are utilized have not been fully ...
D' Alessandro, Angelo, Freeman, Scott, Graham, Brian B, Gu, Sue, Hernandez-Saavedra, Daniel, Kassa, Biruk, Kumar, Rahul, Lee, Michael H, Mickael, Claudia, Reisz, Julie A, Sanders, Linda, Stenmark, Kurt R, Tuder, Rubin M   +12 more
core   +1 more source

Phosphodiesterase-5 inhibitors: Raynaud's and beyond

Indian Journal of Rheumatology, 2017
Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak, Sajal Ajmani, Vikas Agarwal, Durga Prasanna Misra   +3 more
doaj  

The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis

Sexual Medicine, 2018
Introduction: Phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line drugs for erectile dysfunction. Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked with PDE5-I use.
Bing Liu, MD, Linxin Zhu, MM, Jingxiang Zhong, MD, Guohua Zeng, MD, Tuo Deng, MD   +4 more
doaj   +1 more source

Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity

OncoImmunology, 2018
Cancer surgery while necessary for primary tumor removal, has been shown to induce immune suppression and promote metastases in preclinical models and human cancer surgery patients.
Lee-Hwa Tai, Almohanad A. Alkayyal, Amanda L. Leslie, Shalini Sahi, Sean Bennett, Christiano Tanese de Souza, Katherine Baxter, Leonard Angka, Rebecca Xu, Michael A. Kennedy, Rebecca C. Auer   +10 more
doaj   +1 more source

Unmasking hidden risks: The surprising link between PDE5 inhibitors and seizure susceptibility. [PDF]

PLoS One, 2023
Silva ALMD, Nascimento CP, Azevedo JEC, Vieira LR, Hamoy AO, Tiago ACDS, Martins Rodrigues JC, de Araujo DB, Favacho Lopes DC, de Mello VJ, Hamoy M.   +10 more
europepmc   +1 more source

Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. [PDF]

J Sex Med, 2023
Furtado TP, Miranda EP, Deveci S, Jenkins L, Narus J, Nelson C, Mulhall JP.   +6 more
europepmc   +1 more source

The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders. [PDF]

J Thromb Haemost, 2022
Degjoni A, Campolo F, Stefanini L, Venneri MA.   +3 more
europepmc   +1 more source

Future prospects in the treatment of erectile dysfunction: focus on avanafil

Drug Design, Development and Therapy, 2011
Amjad Alwaal, Raed Al-Mannie, Serge Carrier Division of Urology, McGill University Health Centre, Montreal, Quebec, Canada Abstract: The treatment of erectile dysfunction (ED) has been revolutionized in the last 15 years with the introduction of type 5 ...
Alwaal A, Al-Mannie R, Carrier S
doaj  

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties. [PDF]

Pharmaceutics, 2022
Amin KM, El-Badry OM, Abdel Rahman DE, Abdellattif MH, Abourehab MAS, El-Maghrabey MH, Elsaid FG, El Hamd MA, Elkamhawy A, Ammar UM.   +9 more
europepmc   +1 more source